Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 7;9(7):ofac282.
doi: 10.1093/ofid/ofac282. eCollection 2022 Jul.

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

Navina K Birk  1 , Saniya Jain  1 , Louis Massoud  1 , Diya Ramesh  1 , Lea Monday  1 , Bruce Muma  1 , Jonathan Williams  1 , George Alangaden  1 , Mayur Ramesh  1
Affiliations

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

Navina K Birk et al. Open Forum Infect Dis. .

Abstract

We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.

Keywords: COVID-19; immunocompromised hosts; monoclonal antibody; outcomes; sotrovimab.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention . COVID data tracker. 2022. Available at: https://covid.cdc.gov/covid-data-tracker. Accessed 21 February 2022.
    1. Mornese Pinna S, Lupia T, Scabini S, et al. Monoclonal antibodies for the treatment of COVID-19 patients: an umbrella to overcome the storm? Int Immunopharmacol 2021; 101(Pt A):108200. - PMC - PubMed
    1. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602:664–70. - PMC - PubMed
    1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021; 385:1941–50. - PubMed
    1. US Food and Drug Administration . Fact sheet for health care providers: Emergency Use Authorization (EUA) of sotrovimab. Available at: https://www.fda.gov/media/149535/download. Accessed 4 March 2022.